Skip to main content

Advertisement

SpringerLink
Log in

Hepatectomy and immune checkpoint inhibitor treatment for liver metastasis originating from non-cutaneous melanoma: a report of three cases

  • Case report
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

The outcomes of hepatectomy alone for liver metastasis derived from non-cutaneous melanoma are insufficient, and the outcomes of systemic therapy alone are also insufficient, even since the development of immune checkpoint inhibitors (ICIs). We report the cases of three patients, in whom liver metastasis derived from non-cutaneous melanoma was treated with hepatectomy combined with ICI therapy, which was administered in various settings. One patient received ICI treatment for recurrent melanoma and survived 107 months after the first hepatectomy, one patient received both preoperative and adjuvant ICI treatment and has been disease-free for 27 months, and another patient received postoperative ICI treatment after reduction hepatectomy and has been alive with disease for 47 months. Since long-term survival is possible, hepatectomy combined with ICI therapy should be considered for the treatment of liver metastasis derived from non-cutaneous melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

eCT:

Contrast-enhanced computed tomography

DFS:

Disease-free survival

ICI:

Immune checkpoint inhibitor

LM:

Liver metastasis

LM-NCM:

Liver metastasis derived from non-cutaneous melanoma

MST:

Median survival time

NCM:

Non-cutaneous melanoma

OS:

Overall survival

PD-1:

Programmed cell death 1

S:

Segment

References

  1. Chang AE, Karnell LH, Menck HR (1998) The National Cancer Data Base report on cutaneous and noncutaneous melanoma. Cancer 83:1664–1678

    Article  CAS  Google Scholar 

  2. Del Prete V, Chaloupka K, Holzmann D et al (2016) Noncutaneous melanomas: a single-center analysis. Dermatology 232:22–29

    Article  Google Scholar 

  3. Gilain L, Houette A, Montalban A et al (2014) Mucosal melanoma of the nasal cavity and paranasal sinuses. Eur Ann Otorhinolaryngol Head Neck Dis 131:365–369

    Article  CAS  Google Scholar 

  4. Aubin JM, Rekman J, Vandenbroucke-Menu F et al (2013) Systematic review and meta-analysis of liver resection for metastatic melanoma. Br J Surg 100:1138–1147

    Article  Google Scholar 

  5. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526

    Article  CAS  Google Scholar 

  6. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

    Article  CAS  Google Scholar 

  7. Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330

    Article  CAS  Google Scholar 

  8. Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532

    Article  CAS  Google Scholar 

  9. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998–1012

    Article  CAS  Google Scholar 

  10. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516

    Article  CAS  Google Scholar 

  11. McArthur GA, Chapman PB, Robert C et al (2014) Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323–332

    Article  CAS  Google Scholar 

  12. Flaherty KT, Robert C, Hersey P et al (2015) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–114

    Article  Google Scholar 

  13. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:123–134

    Article  Google Scholar 

  14. Allen PJ, Coit DG (2002) The surgical management of metastatic melanoma. Ann Surg Oncol 9:762–770

    Article  Google Scholar 

  15. Eggermont AMM, Chiarion-Sileni V, Grob JJ et al (2019) Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. Eur J Cancer 119:1–10

    Article  CAS  Google Scholar 

  16. Eggermont AMM, Blank CU, Mandala M et al (2020) Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial. J Clin Oncol 38:3925–3936

    Article  CAS  Google Scholar 

  17. Ascierto PA, Del Vecchio M, Mandalá M et al (2020) Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 21:1465–1477

    Article  CAS  Google Scholar 

  18. Testori AAE, Chiellino S, van Akkooi ACJ (2020) Adjuvant therapy for melanoma: past, current, and future developments. Cancers (Basel) 12:1994

    Article  CAS  Google Scholar 

  19. Huang AC, Orlowski RJ, Xu X et al (2019) A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med 25:454–461

    Article  CAS  Google Scholar 

  20. Shivaji UN, Jeffery L, Gui X et al (2019) Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol. https://doi.org/10.1177/1756284819884196

    Article  PubMed  PubMed Central  Google Scholar 

  21. Sihag S, Ku GY, Tan KS et al (2021) Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. Thorac Cardiovasc Surg 161:836–843

    Article  Google Scholar 

  22. Bott MJ, Cools-Lartigue J, Tan KS et al (2018) Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg 106:178–183

    Article  Google Scholar 

  23. Hai S, Hatano E, Okada T et al (2018) Is noncurative hepatic resection justified for advanced hepatocellular carcinoma? Am Surg 84:1938–1944

    Article  Google Scholar 

  24. Komatsu S, Kido M, Tanaka M et al (2019) Clinical relevance of reductive hepatectomy for barcelona clinic liver cancer stages B and C advanced hepatocellular carcinoma: a single-center experience of 102 patients. World J Surg 43:2571–2578

    Article  Google Scholar 

  25. Ao W, Wang J, Mao G et al (2019) Primary hepatic melanoma: a case report of computed tomography and magnetic resonance imaging findings. Medicine (Baltimore) 98:e16165

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery I, Hokkaido University Hospital, Kita-ku, Kita 15, Nishi 7, Sapporo, Hokkaido, 060-8638, Japan

    Yoh Asahi, Toshiya Kamiyama, Tatshiko Kakisaka, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Yuzuru Sakamoto, Takaya Ishikawa, Hirofumi Kamachi & Akinobu Taketomi

  2. Department of Surgical Pathology, Hokkaido University Hospital, Kita-ku, Kita 15, Nishi 7, Sapporo, Hokkaido, 060-8638, Japan

    Tomoko Mitsuhashi

  3. Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University Graduate School of Medicine, Kita-ku, Kita 15, Nishi 7, Sapporo, Hokkaido, 060-8638, Japan

    Satoshi Takeuchi & Hirotoshi Dosaka-Akita

Authors
  1. Yoh Asahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshiya Kamiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tatshiko Kakisaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tatsuya Orimo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shingo Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akihisa Nagatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuzuru Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takaya Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hirofumi Kamachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tomoko Mitsuhashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Satoshi Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hirotoshi Dosaka-Akita
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Akinobu Taketomi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoh Asahi.

Ethics declarations

Conflict of interest

None of the authors have any conflicts of interest to disclose.

Informed consent

Informed consent was obtained from all individual participants.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Asahi, Y., Kamiyama, T., Kakisaka, T. et al. Hepatectomy and immune checkpoint inhibitor treatment for liver metastasis originating from non-cutaneous melanoma: a report of three cases. Int Canc Conf J 10, 274–279 (2021). https://doi.org/10.1007/s13691-021-00495-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13691-021-00495-x

Keywords

Search

Navigation